Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Dow Jones

06 Feb

By Peter Loftus

Eli Lilly, the world's biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast.

-- Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter.

-- Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier.

-- Mounjaro's revenue rose to $3.53 billion, from $2.63 billion a year earlier.

Investor confidence in the anti-obesity drug market's potential has been shaken in recent months, because sales of Zepbound and Novo Nordisk's Wegovy have come in lower than expected in some quarters. Both stocks are down since last summer.

Lilly had already previewed quarterly sales and given a 2025 revenue forecast last month. That hit the stock, because sales of Mounjaro and Zepbound were growing more slowly than expected.

Lilly's stock climbed nearly 1% premarket Thursday.

Overall, for the fourth quarter:

-- Revenue rose 45% to $13.53 billion. Aside from Mounjaro and Zepbound, sales also rose for cancer drug Verzenio and psoriasis drug Taltz.

-- Adjusted fourth-quarter earnings totaled $5.32 a share.

-- That topped the FactSet analysts' consensus estimate of $5.01 a share.

-- For 2025, Lilly predicts earnings of $22.50 to $24 per share, leaving room to beat the consensus forecast of $22.76.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

February 06, 2025 08:18 ET (13:18 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509755302"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509755302\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2509755302?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509755302","market":"hk","top_or_hot":-1,"title":"Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Peter Loftus \n</p>\n<p>\n     Eli Lilly, the world's biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. \n</p>\n<p>\n     -- Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter. \n</p>\n<p>\n     -- Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier. \n</p>\n<p>\n     -- Mounjaro's revenue rose to $3.53 billion, from $2.63 billion a year earlier. \n</p>\n<p>\n     Investor confidence in the anti-obesity drug market's potential has been shaken in recent months, because sales of Zepbound and Novo Nordisk's Wegovy have come in lower than expected in some quarters. Both stocks are down since last summer. \n</p>\n<p>\n     Lilly had already previewed quarterly sales and given a 2025 revenue forecast last month. That hit the stock, because sales of Mounjaro and Zepbound were growing more slowly than expected. \n</p>\n<p>\n     Lilly's stock climbed nearly 1% premarket Thursday. \n</p>\n<p>\n     Overall, for the fourth quarter: \n</p>\n<p>\n     -- Revenue rose 45% to $13.53 billion. Aside from Mounjaro and Zepbound, sales also rose for cancer drug Verzenio and psoriasis drug Taltz. \n</p>\n<p>\n     -- Adjusted fourth-quarter earnings totaled $5.32 a share. \n</p>\n<p>\n     -- That topped the FactSet analysts' consensus estimate of $5.01 a share. \n</p>\n<p>\n     -- For 2025, Lilly predicts earnings of $22.50 to $24 per share, leaving room to beat the consensus forecast of $22.76. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 06, 2025 08:18 ET (13:18 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-06 21:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Peter Loftus \n</p>\n<p>\n     Eli Lilly, the world's biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. \n</p>\n<p>\n     -- Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter. \n</p>\n<p>\n     -- Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier. \n</p>\n<p>\n     -- Mounjaro's revenue rose to $3.53 billion, from $2.63 billion a year earlier. \n</p>\n<p>\n     Investor confidence in the anti-obesity drug market's potential has been shaken in recent months, because sales of Zepbound and Novo Nordisk's Wegovy have come in lower than expected in some quarters. Both stocks are down since last summer. \n</p>\n<p>\n     Lilly had already previewed quarterly sales and given a 2025 revenue forecast last month. That hit the stock, because sales of Mounjaro and Zepbound were growing more slowly than expected. \n</p>\n<p>\n     Lilly's stock climbed nearly 1% premarket Thursday. \n</p>\n<p>\n     Overall, for the fourth quarter: \n</p>\n<p>\n     -- Revenue rose 45% to $13.53 billion. Aside from Mounjaro and Zepbound, sales also rose for cancer drug Verzenio and psoriasis drug Taltz. \n</p>\n<p>\n     -- Adjusted fourth-quarter earnings totaled $5.32 a share. \n</p>\n<p>\n     -- That topped the FactSet analysts' consensus estimate of $5.01 a share. \n</p>\n<p>\n     -- For 2025, Lilly predicts earnings of $22.50 to $24 per share, leaving room to beat the consensus forecast of $22.76. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 06, 2025 08:18 ET (13:18 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2509755302","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509755302","pubTimestamp":1738847880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Eli Lilly, the world's biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast.-- Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter.-- Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier.-- Mounjaro's revenue rose to $3.53 billion, from $2.63 billion a year earlier.Investor confidence in the anti-obesity drug market's potential has been shaken in recent months, because sales of Zepbound and Novo Nordisk's Wegovy have come in lower than expected in some quarters. Both stocks are down since last summer.Lilly had already previewed quarterly sales and given a 2025 revenue forecast last month. That hit the stock, because sales of Mounjaro and Zepbound were growing more slowly than expected.-- Revenue rose 45% to $13.53 billion. Aside from Mounjaro and Zepbound, sales also rose for cancer drug Verzenio and psoriasis drug Taltz.-- Adjusted fourth-quarter earn","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"盈利超出预期后礼来公司股价上涨——华尔街日报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"By Peter Loftus \n\n\n     Eli Lilly, the world's biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. \n\n\n     -- Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter. \n\n\n     -- Revenue from Zepbound leapt to $1.91 billion, up from $175.8 million a year earlier. \n\n\n     -- Mounjaro's revenue rose to $3.53 billion, from $2.63 billion a year earlier. \n\n\n     Investor confidence in the anti-obesity drug market's potential has been shaken in recent months, because sales of Zepbound and Novo Nordisk's Wegovy have come in lower than expected in some quarters. Both stocks are down since last summer. \n\n\n     Lilly had already previewed quarterly sales and given a 2025 revenue forecast last month. That hit the stock, because sales of Mounjaro and Zepbound were growing more slowly than expected. \n\n\n     Lilly's stock climbed nearly 1% premarket Thursday. \n\n\n     Overall, for the fourth quarter: \n\n\n     -- Revenue rose 45% to $13.53 billion. Aside from Mounjaro and Zepbound, sales also rose for cancer drug Verzenio and psoriasis drug Taltz. \n\n\n     -- Adjusted fourth-quarter earnings totaled $5.32 a share. \n\n\n     -- That topped the FactSet analysts' consensus estimate of $5.01 a share. \n\n\n     -- For 2025, Lilly predicts earnings of $22.50 to $24 per share, leaving room to beat the consensus forecast of $22.76. \n\n\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2025 08:18 ET (13:18 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}